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Abstract
Background: The efficacy and biosafety of lentiviral gene transfer is influenced by the design of the vector. To this
end, properties of lentiviral vectors can be modified by using cis-acting elements such as the modification of the
U3 region of the LTR, the incorporation of the central flap (cPPT-CTS) element, or post-transcriptional regulatory
elements such as the woodchuck post-transcriptional regulatory element (WPRE). Recently, several studies
evaluated the influence of the incorporation of insulators into the integrating lentiviral vector genome on
transgene expression level and position effects.
Methods: In the present study, the influence of the matrix attachment region (MAR) of the mouse immunoglobulin-
(Ig-) or the chicken lysozyme (ChL) gene was studied on three types of HIV-1-derived lentiviral vectors: self-
inactivating (SIN) lentiviral vectors (LV), double-copy lentiviral vectors (DC) and non-integrating lentiviral vectors
(NILVs) in different cell types: HeLa, HEK293T, NIH-3T3, Raji, and T Jurkat cell lines and primary neural progenitors.
Results and Discussion: Our results demonstrate that the Ig- MAR in the context of LV slightly increases
transduction efficiency only in Hela, NIH-3T3 and Jurkat cells. In the context of double-copy lentiviral vectors, the
Ig- MAR has no effect or even negatively influences transduction efficiency. In the same way, in the context of
non-integrating lentiviral vectors, the Ig- MAR has no effect or even negatively influences transduction efficiency,
except in differentiated primary neural progenitor cells.
The ChL MAR in the context of integrating and non-integrating lentiviral vectors shows no effect or a decrease of
transgene expression in all tested conditions.
Conclusions: This study demonstrates that MAR sequences not necessarily increase transgene expression and that
the effect of these sequences is probably context dependent and/or vector dependent. Thus, this study highlights
the importance to consider a MAR sequence in a given context. Moreover, other recent reports pointed out the
potential effects of random integration of insulators on the expression level of endogenous genes. Taken together,
these results show that the use of an insulator in a vector for gene therapy must be well assessed in the particular
therapeutic context that it will be used for, and must be balanced with its potential genotoxic effects.
Background
Lentiviral vectors are among the best gene transfer tools for
both dividing and non-dividing cells. Their relatively recent
development has been underpinned by accumulated under-
standing of the biology of the human immunodeficiency
virus (HIV) and experience with oncoretrovirus-derived
vectors. The biosafety of gene transfer tools depends in part
on their efficacy, and efficacy can be optimized by rational
vector design. Over the past ten years, many improvements
have been made to lentiviral vector systems so as to
improve their biosafety and performance.
The effects of various cis-acting modifications have
been evaluated as a means to increase the transduction
efficiency of lentiviral vectors and consequently reduce
the amount of vector needed for efficient transduction.
Self-inactivating (SIN) vectors with deletions in the U3
enhancer region of the LTR (Long Terminal Repeat)
have been developed and display higher biosafety,
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transgene expression than the unmodified parental vec-
tors both in MLV- and HIV-1-derived vectors [1-5].
The incorporation of the lentiviral flap sequence, or
cPPT-CTS, enhances transduction efficiency by 2 to 10
fold in many cell types both in vitro and in vivo, propor-
tionally reducing the quantity of vector needed for high
frequency transduction [6-9]. The incorporation of the
regulatory sequence WPRE [10,11] or the 3’ UTR of the
tau or tyrosine hydroxylase genes into the transgene
expression cassette also enhances transgene expression
by several fold [12]. S/MAR (Scaffold/Matrix Attach-
ment Region) and LCR (Locus Control Region) are insu-
lators, and their contribution to expression has been
studied in the context of LV. Insulators are DNA
sequence elements that prevent inappropriate interac-
tions between adjacent chromatin domains (for review
see [13]). The Ig- gene MAR, but not the chicken lyso-
zyme gene MAR, has been reported to enhance trans-
gene expression in hepatic cells by about 4-fold both
in vitro and in vivo [14]. The incorporation of a SAR
from the human interferon-b gene into SIN lentiviral
vector backbone increases average GFP expression in
human ES cells [15] and human CD34+ hematopoietic
cells [16]. The inclusion of the SAR together with the
LCR (5’HS4) from the chicken b-globin locus reduced
the variability in GFP expression, i.e. repressive position
effects, in human ES cells [15] and human CD34+
hematopoietic cells [16]. The LCR (5’HS4) from the
chicken b-globin locus has also been reported to pre-
vent, partially or fully, positional effects on retrovirus-
driven transgene expression in erythropoietic cells
[17,18]. However, this could not be confirmed in
another context, where the same sequences had no
effect in dividing RN33B neural stem cells [19].
Another factor that may influence the use of insulators
for gene transfer is their position in the vector backbone,
and more specifically their presence on both sides of the
expression cassette. Indeed, MARs have been shown to
be more effective when flanking the transgene expression
cassette by preventing positional effects and by prevent-
ing negative epigenetic modifications of the integrated
DNA [20]. In oncoretroviral and LV, a simple way to
obtain vectors where a MAR flanks the expression cas-
sette is to clone it in place of the U3 region of the 3’LTR.
After reverse transcription, the MAR is copied into the
U3 region of the 5’LTR giving rise to a proviral genome
that contains the expression cassette flanked by the
MAR. Recent studies demonstrated that the insertion of
the 1.2 kb HS4 MAR sequence in the U3 region of a DC
lentiviral vector can reduce the RT process and conse-
quently reduce the titer and efficacy of the vector
[21-23]. However, this effect was not observed with a 250
bp MAR sequence [21].
Because insulators can affect the expression of genes
placed at long distance, it is also important to carefully
consider the potential genotoxic effect of MARs when
placed in a vector leading to integration of the MAR
into the target cell genome. This is all the more impor-
tant as integration of lentiviral vectors is preferentially
targeted in active transcription units, making the lentivi-
rally-driven integration of MARs potentially genotoxic.
For instance, in the Burkitt’s lymphoma, expression of
c-myc gene is deregulated by its translocation near the
HS4 region of the murine immunoglobulin heavy chain.
In an in vitro study, using a luciferase reporter system,
it has been shown that the murine HS4 region activates
the c-myc promoter activity by 46-fold and the human
HS4 region by 14-fold [24]. Moreover, a recent work
showed that aberrant expression of the gene that
encodes the STAB1 protein, which binds to insulator
sequence, was responsible for the generation of brain
tumors [25]. However, in the context of integrating len-
tiviral gene transfer, the genotoxicity issue has been stu-
died relatively little, and few recent reports gave rise to
contradictory conclusions [26-29].
A solution to the potential genotoxicity of LV was the
development of non-integrative lentiviral vectors
(NILVs), as it was shown by us [30] and other groups
[31,32]. These vectors remain as episomal genomes in
the nucleus of the transduced cells (for review see
[33-35]) and therefore avoid the risk of genotoxicity by
insertional mutagenesis. They have great potential for
clinical use, particularly in non-dividing cells where
their episomal genome remains stable for at least one
year [32]. However, transgene expression from such vec-
tors may be 2 to 10 times less strong than that from
otherwise similar integrative control vectors [1,30,36,37].
It would therefore be valuable to improve the transduc-
tion efficiency of NILVs so as to reduce the quantity of
vector needed. Although insulators have been studied in
integrating lentiviral vectors, their effects on transgene
expression from NILVs have never been investigated.
We incorporated the MARs from the immunoglobulin-
(Ig-) and the chicken lysozyme genes into three lentiviral
vector backbones (SIN, DC and NILV) and assessed the
effects in vitro in several cell types. The presence of these
MARs in SIN lentiviral vectors, DC lentiviral vectors and
NILVs did not result in significant or relevant systematic
enhancement of transgene expression in the cell types
tested, and indeed, in some cases led to a decrease in
transgene expression.
Methods
Plasmids
Vector design is summarized in the Additional File 1.
Encapsidation plasmids expressing a functional inte-
grase (p8.91 INWT) or a N mutant integrase (p8.91 INN)
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consists of the replacement of the 262RRK motif of the
N region of the integrase (IN) coding sequence with
AAH, the equivalent motif of the Moloney murine leu-
kemia virus IN.
The immunoglobulin gamma (Ig-)g e n eM A R
sequence was amplified by PCR from genomic DNA of
C57B6 mice (Genbank sequence V00777, nucleotides
3345 to 3758) with the following primers, which created
NheI and SalI restriction sites at the 5’ and 3’ ends,
respectively, of the Ig- MAR sequence: mar1:
5’GGCTAGCAGGGCATAAACTGCTTTATCCAGT
G3’;m a r 2 :5 ’CGTCGACATAACTTAATGACTCTAA
AGTAGTTTC3’. The PCR product was introduced in
place of the NheI-SalI fragment of the previously
described pTrip-CMV-GFP-WPRE [30] to generate
Trip- MARIg-CMV-GFP-WPRE.
The plasmids pTrip-CMV-LUC-WPRE and Trip-
MARIg-CMV-LUC-WPRE were generated by replacing
GFP sequence (XhoI-SpeI fragment) in pTrip-CMV-GFP-
WPRE and Trip-MARIg-CMV-GFP-WPRE, respectively,
with the luciferase sequence (XhoI-XbaI fragment from
pGL3 (Promega)).
The plasmid pTrip-EF1-LUC-MARIgKdc-SIN is derived
from pTrip-EF1-EGFP-SIN in which a multiple cloning
site has been inserted in place of the U3 deletion in the 3’
L T R .T h eE G F Ps e q u e n c e( B s r G I -X h o If r a g m e n t )w a s
replaced with the luciferase sequence (BsrGI-BamHI
fragment from plasmid pGL3 (Promega)) to generate
pTrip-EF1-LUC-dc-SIN. The MAR Ig sequence was
inserted in place of the NheI-SalI fragment in pTrip-EF1-
LUC-SIN to generate pTrip-EF1-LUC-MARIgKdc-SIN.
The plasmids Trip-MARChLS-CMV-LUC-WPRE and
Trip-MARChLAS-CMV-LUC-WPRE were constructed by
introducing the MAR sequence from the chicken lyso-
zyme (ChL) gene (SmaI-BsrBI fragment) from the pre-
viously described pPGA1 [38]) into the SalI restriction
site in pTrip-CMV-LUC-WPRE in sense and anti-sense
orientations, respectively.
Lentiviral vector production and purification
Lentiviral vectors were generated by transient transfection
of 293T cells by the calcium phosphate precipitation
method as described previously [30]. For all experi-
ments, the LUC vector with the MAR sequence and
the corresponding control LUC vector without the
MAR sequence were produced simultaneously. Vectors
were titrated by assaying HIV p24 Gag antigen in each
stock by ELISA (HIV-1 P24 antigen assay; Beckman
Coulter, Fullerton, CA).
Cell lines and primary cultures
Human epithelial HeLa and HEK293T cells and murine
NIH-3T3 cells were grown in Dulbecco’sm o d i f i e d
medium supplemented with 100 U/mL penicillin,
100 μg/mL streptomycin and 10% fetal calf serum
(FCS). The human Jurkat T-cell line and human Raji B-
cell line were cultured in RPMI 1640 medium contain-
ing 10% FCS, 1% HEPES, 1% glutamine, 100 U/ml peni-
cillin and 100 mg/ml streptomycin. Neural telencephalic
progenitor cultures were generated and maintained as
described previously [39].
Transduction of cells
HEK293T, Hela and NIH-3T3 cells were seeded at densi-
ties of 15,000, 5,000 and 6,500 cells per well, respectively,
in 96-well plates. The cells were transduced 24 hours later
in medium supplemented with 1 μMD E A E - D e x t r a n .
Contact with the vectors was allowed for 4 hours then the
medium was removed and replaced with fresh medium.
R a j ia n dJ u r k a tc e l l sw e r es e eded in 24-well plates at a
density of 100,000 cells per well. These cells were infected
and maintained in RPMI 1640 medium supplemented
with 10% FCS, 1% HEPES, 1% glutamine and 100 μg/mL
each penicillin and streptomycin. After 12 hours of contact
with the virions, the cells were washed and the RPMI
medium was replaced.
Neural progenitor cells were seeded in 96-well plates
coated with an adherent substrate (gelatin and laminin)
at a density of 10,000 cells per well in a N2 standard
medium supplemented with 10 ng/ml bFGF (Roche
Diagnostics, Nutley, NJ). These cultures were maintained
for 2 days then transduced with various doses of vector.
After 24 hours of incubation with the vector, the medium
was replaced with either standard medium (N2 + bFGF)
or standard medium supplemented with 10% fetal calf
serum to induce glial differentiation.
Luciferase assay
Luciferase activity was measured 72 h after transduction
using the Promega Bright-Glo Luciferase Assay Kit
according to the manufacturer’s protocol. The cells were
rinsed with 1X PBS and 100 μl of Glo Lysis Buffer was
added directly in the wells. The plates were incubated
for 5 minutes at room temperature, then the lysate
transferred into 0.5 ml Eppendorf tubes and used
directly for luciferase activity assay or stored at -80°C.
The tubes were incubated for 5 minutes at room tem-
perature and stored at -80°C. The firefly luciferase activ-
ity assay was performed following the manufacturer’s
instructions by adding 10 μlo fB r i g h t - G l o ™Assay
Reagent to an equal volume of sample and the lumines-
cence was measured with a luminometer.
Statistical analyses
GraphPad Prism 5 software (GraphPad software, Inc)
was used for all statistical analyses. Results were ana-
lyzed using two-way ANOVA followed by Bonferroni
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except for the results reported in Figures 2a and 2b for
which an unpaired t test was used.
Results and discussion
We studied the effects of the incorporation of the Ig
MAR on transgene expression from three types of LV
containing a luciferase expression cassette (see Addi-
tional File 1 for vector design). Three types of cells
(HEK293T, Hela and NIH-3T3) were transduced in
triplicate with a series of doses of the vector, and luci-
ferase activity was measured 72 hours later. In LV, luci-
ferase activity was significantly enhanced by the
presence of the Ig MAR in HEK293T (Figure 1a, two-
way ANOVA, p = 0.0004) and Hela cells (Figure 1b,
two-way ANOVA, p = 0.0190), but not in 3T3 cells
(Figure 1c, two-way ANOVA, p = 0.2214). The enhance-
ment of expression by Ig MAR was however moderate,
and always less than double; these findings are discor-
dant with those previously described for hepatic cells by
Figure 1 Effects of the Ig MAR in three lentiviral vectors. Three types of cells (HEK293T, Hela and NIH-3T3) were transduced in triplicate
with a series of doses of the vector (ranging from 0.1 to 15 ng of p24, measured by ELISA), and luciferase activity was measured 72 hours later.
HEK293T, Hela and NIH-3T3 cells were seeded at densities of 15,000, 5,000 and 6,500 cells per well, respectively, in 96-well plates. SIN integrating
(IN WT) lentiviral vectors bearing a CMV-LUC expression cassette, double-copy (DC) integrating lentiviral vectors bearing an EF1-LUC expression
cassette and non-integrating (IN N) lentiviral vectors bearing a CMV-LUC expression cassette were used without (white columns) or with (black
columns) the Ig MAR. Statistical analysis was performed using a two-way ANOVA, and statistical significance of the Bonferroni post-test is
represented on the relevant bars (* for p < 0.05, ** for p < 0.01 and *** for p < 0.001).
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of transgene expression level using the same Ig MAR.
MARs have been shown to be more effective in some
cases when flanking the transgene expression cassette
[20]. We therefore constructed DC in which the Ig
MAR was inserted into the U3 region of the 3’LTR
which results after RT in an integrative vector flanked
by the MAR inserted in both U3 regions. Surprisingly,
transgene expression from the DC was significantly
weaker than that from control vectors without MAR,
in both HEK293T cells (Figure 1d, two-way ANOVA,
p = 0.0041) and Hela cells (Figure 1e, two-way
ANOVA, p < 0.0001); there was no difference between
MAR DC vectors and control vectors in NIH-3T3 cells
(Figure 1f, two-way ANOVA, p = 0.1167). Thus, the
presence of two copies of Ig MAR flanking the trans-
gene does not enhance expression in these cells, but
decreases expression by up to about 50%. This may be
because the MAR-containing DC vectors are longer
than the control constructs; increased length may
reduce the encapsidation efficiency [23,40,41] or result
in lower processing by the HIV reverse transcriptase,
which is a poorly efficient enzyme [42,43]. This was
confirmed by recent studies demonstrating that the
insertion of a 1.2 kb HS4 MAR in the U3 region of
an integrative LV can reduce the RT process and con-
sequently reduce the titer of the vector [21-23]. How-
ever, this effect was influenced by the length of the
incorporated sequence as the negative effect could not
be observed with a 250 bp sequence corresponding to
t h ec o r ee l e m e n to ft h eH S4 MAR [21]. Our results
suggest the negative effect on RT processing could
already occur with a 420 bp sequence.
To test the effects of the Ig MAR in an episomal con-
text, we produced NILVs containing the Igk MAR and
used these constructs to transduce HEK293T, HeLa and
NIH-3T3 cells. Unlike what we observed with integrative
vectors, Ig MAR significantly reduced luciferase expres-
sion in Hela (Figure 1h, two-way ANOVA, p = 0.0013)
and NIH-3T3 (Figure 1i, two-way ANOVA, p = 0.0004)
cells. In HEK293T cells, MAR did not significantly affect
expression (Figure 1g, two-way ANOVA, p = 0.0647),
except at the highest dose of vector (Figure 1g; at the
highest dose about 60% stronger expression than the
control vector; Bonferroni post-test p < 0.001). In conclu-
sion, the Igk MAR does not generally enhance transgene
expression from an episomal lentiviral vector.
The cell-type may determine the effects of the MAR, so
we investigated its effects in cells in which immunoglobu-
lin- chains are normally expressed, i.e. lymphocytes. We
transduced Raji (human B lymphoblastoma cells) and
Jurkat cells (human T lymphoblastoma cells) with an inte-
grating LV expressing luciferase, with or without the Ig
MAR. In Raji cells, the MAR did not influence luciferase
expression at all (Figure 2a, unpaired t test, p = 0,5998),
whereas in Jurkat cells the presence of MAR was asso-
ciated with a small but significant increase in expression
(28%, unpaired t test, p = 0.0228; Figure 2b). Thus, the
presence of Ig MAR in an LV does not lead to a large
increase of transgene expression in lymphocytic cells.
MARs facilitate transcription by epigenetic mechan-
isms involving chromatin remodelling, histone hyperace-
tylation and DNA demethylation [20]. We therefore
tested the influence of the Ig MAR in a cell culture in
which transgene expression from lentiviral vectors is
strongly repressed by epigenetic inhibition. Expression
Figure 2 Effects of the Igk MAR in lymphoblastoma and neural progenitor cells.R a j i( a ) ,J u r k a t( b )a n dn e u r a lp r o g e n i t o r( c )c e l l sw e r e
transduced using SIN integrating (IN WT) or non-integrating (IN N) lentiviral vectors expressing the luciferase transgene with (black columns) or
without (white columns) the Ig MAR. Raji and Jurkat cells were seeded in 24-well plates at a density of 100,000 cells per well. Neural progenitor
cells were seeded in 96-well plates at a density of 10,000 cells per well in a N2 standard medium supplemented with 10 ng/ml bFGF. After
contact with the vectors, neural progenitors were maintained undifferentiated or were glially differentiated by addition of 10% fetal calf serum in
the culture medium. Unpaired t test was performed to analyze results of figures a and b and two-way ANOVA for figure c. Statistical significance
of the t test (figure b, * for p < 0.05) or the Bonferroni post-test (figure c, *** for p < 0.001) are represented on the relevant columns.
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genitor cells is greatly enhanced after serum-induced
differentiation of these cells into the glial fate [39]. We
used this model, and first confirmed that epigenetic
repression inhibited transgene expression from lentiviral
vectors: we transduced neural progenitor cell cultures
with LV expressing GFP (data not shown) or luciferase
(see Additional File 2) and treated the cells with sodium
butyrate, an inhibitor of histone deacetylases (treatment
with sodium butyrate leads to a massive histone hypera-
cetylation and generally induces expression from
silenced genes). Following treatment with sodium buty-
rate, luciferase expression increased substantially (over
10-fold increase in undifferentiated cells), confirming
the strong epigenetic repression of transgene expression
from our lentiviral vector in these cells (see Additional
File 2). We then transduced undifferentiated and serum-
differentiated neural progenitor cultures with NILVs
(with and without the Ig MAR) and assayed transgene
expression. Transgene expression was significantly
(about 60%) higher from vectors with than without the
MAR (Figure 2c, two-way ANOVA, p < 0.0001) only in
glially differentiated cultures (Figure 2c, Bonferroni
post-test, p < 0.001) and not in undifferentiated cultures
(Figure 2c, Bonferroni post-test, p > 0.05). Thus the
observed moderate MAR-associated increase in expres-
sion was independent of epigenetic repression, and
appeared to be a cell-type specific effect.
We tested the effects of another insulator, the chicken
lysozyme (ChL) gene MAR. Luciferase-expressing LV
and NILV lentivectors were produced, containing or not
the ChL MAR, incorporated in sense or antisense orien-
tation upstream of the cPPT-CTS region (see Additional
Figure 1). In Hela cells, the presence of the ChL MAR in
a NILV did not significantly affect the transgene expres-
sion (Figure 3a, two-way ANOVA, p = 0.4199). The same
result was observed in NIH-3T3 cells (Figure 3b, two-
way ANOVA, p = 0.2349), and the sense-oriented MAR
even led to a ~70% decrease of the transgene expression
at the highest dose (Figure 3b, Bonferroni post-test, p >
0.05). In progenitor cell cultures, the ChL MAR had large
and significant negative effects on transgene expression
from both integrating and NILVs. In the integrating vec-
tor, the significance was very high (Figure 3c, two-way
ANOVA, p < 0.0001) especially in differentiated cells in
which the decrease of transgene expression was up to
~11-fold (Figure 3c, sense ChL, Bonferroni post-test, p <
0.001 and antisense ChL, Bonferroni post-test, p < 0.001).
In the NILV, ChL MAR similarly reduced expression
with high statistical significance (Figure 3d, two-way
ANOVA, p < 0.0001) especially in glially differentiated
cells (Figure 3d, sense ChL, Bonferroni post-test, p <
0.001 and antisense ChL Bonferroni post-test, p < 0,001).
Conclusion
In conclusion, the Ig MAR does not systematically
increase transgene expression from lentiviral vectors –
whether integrative, double-copy or non-integrating – in
the cell lines tested, or even in lymphocytic cells or epi-
genetically repressed cells. The ChL MAR may either
not affect transgene expression or have moderate or
strong negative effects on transgene expression, depend-
ing on the cell type. These results are summarized in
the following Table 1:
Our findings highlight the importance of studying
the effects of particular MARs in appropriate model
systems as they may not lead to the expected increase
of transgene expression. It seems that alternative ways
to enhance transgene expression are required, for
example using strong promoters, cis-acting non-coding
sequences [12] or, as was very recently demonstrated
for NILVs in some cell types, by optimizing the vector
backbone by deleting particular parts of the U3
region [1].
Figure 3 Effects of the chicken lysozyme (ChL) gene MAR on integrating (IN WT) and non-integrating (IN N) lentiviral vectors. Hela (a)
and NIH-3T3 (b) and neural progenitor (c and d) cells were transduced with integrating (IN WT) or non-integrating (IN N) vectors containing a
luciferase transgene expression cassette without (white columns) the ChL MAR or with a sense-oriented (black columns) or antisense-oriented
(grey columns) ChL MAR. Statistical analysis was performed using a two-way ANOVA, and statistical significance of the Bonferroni post-test is
represented on the relevant bars (* for p < 0.05, ** for p < 0.01 and *** for p < 0.001).
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Additional File 1: Plasmids used for lentiviral production. Three
plasmids are cotransfected in HEK293T cells for vector production. The
vector plasmid contains the expression cassette and a MAR subcloned
upstream the flap (cPPT-CTS) sequence, in sense (Igk or ChL MAR) or
antisense (ChL) orientation. For double-copy vectors, the Igk MAR is
subcloned in place of the U3 region in the 5’ LTR, in sense orientation.
The encapsidation plasmid contains the gag and pol genes. For the
production of the non-integrative lentiviral vectors, the pol gene is
mutated within the integrase coding sequence (
262AAH substitution). For
the production of integrative (SIN) or double-copy (DC) vectors, the WT
integrase sequence is used. The envelope plasmid contains an
expression cassette of the VSV envelope glycoprotein under the control
of a CMV promoter.
Additional File 2: Effect of differentiation of neural progenitor cells
on lentiviral transduction efficiency. Neural progenitor cells were
transduced with a luciferase expressing lentiviral vector (integrating) and
kept in medium keeping them in an undifferentiated state or glially
differentiated state (by addition of 10% FCS). Differentiation of the cells
by FCS leads to an increase of the transgene expression. Moreover, the
addition of butyrate (5 mM) in the medium after transduction leads to a
high enhancement of expression, particularly in undifferentiated cells,
highlighting strong negative epigenetic regulation of the transgene.
List of abbreviations
ANOVA: ANalysis Of VAriance; ChL: Chiken Lysozyme; cPPT-CTS: Central
Polypurine Tract-Central Termination Sequence; DC: Double Copy Lentiviral
Vector; ELISA: Enzyme Linked ImmunoSorbent Assay; GFP: Green Florescence
Protein; HIV: Human Immunodeficiency Virus; HS4: Hypersensitive Site 4; Ig-κ:
immunoglobulin-κ; IN: Integrase; LTR: Long Terminal Repeat; LUC: Luciferase;
LV: Integrating Lentiviral Vector; MAR: Matrix Attachment Region; NILV: Non
Integrative Lentiviral Vector; PCR: Polymerase Chain Reaction; RLU: Relative
Light Unit; RT: Reverse Transcriptase; SAR: Scaffold Attachment region; SIN:
Self Inactivating; STAB1: Special AT-rich Sequence Binding protein 1; UTR:
Untranslated Region
Acknowledgements
We thank Professor Nicolas Mermod (Université de Genève, Switzerland)
for providing us with the ChL MAR. We thank Dr Marie-José Lecomte
for critical reading of the manuscript. This work was supported by
grants from European FP6 (INTEGRA NEST-Adventure contract #29025
and RESCUE contract #518233), AFM, IRME and Rétina France. NG
received a fellowship from the French Ministère de l’enseignement
supérieur et de la recherche and SP from the French Ministère de
l’enseignement supérieur et de la recherche and the Fondation de
France.
Author details
1CRICM - Centre de Recherche de l’Institut du Cerveau et de la Moelle
Epinière - UPMC/INERM UMR_S975/CNRS UMR7225, Equipe de
Biotechnologie et Biothérapie, 83 boulevard de l’Hôpital, 75013 Paris, France.
2NewVectys - 109 rue du Faubourg Saint-Honoré, 75008 Paris, France.
3Unit
of Gene Therapy & Stem Cell Biology, Ophthalmology Department of the
University of Lausanne, Jules-Gonin Eye Hospital, avenue de France 15, 1004
Lausanne, Switzerland.
4Neuronal Survival Unit, Department of Experimental
Medical Science, Wallenberg Neuroscience Center, BMC A10, 221 84 Lund,
Sweden.
5CRC MIRcen - Laboratoire INSERM - Modélisation des biothérapies,
18, route du Panorama, 92265, Fontenay-aux-roses, France.
Authors’ contributions
Conceived, designed and performed the experiments: NG, DH, SP, LA., SU,
CSe and CSa. Supervised the work : CSa and JM. Participated to the article
writing: CSa, NG and JM. All authors read and approved the final manuscript.
Authors’ information
Current address of S.P.: Unit of gene therapy and stem cell biology Jules-
Gonin Eye Hospital, 15 avenue de France 1004 Lausanne, Switzerland.
Current address of L.A.: Neuronal Survival Unit, Department of Experimental
Medical Science, Wallenberg Neuroscience Center, Lund University, 221 84
Lund, Sweden.
Current address of C.Se.: MIRCen laboratoire INSERM - Modélisation des
Biothérapies -18 route du Panorama, Fontenay-aux-Roses, 92265 France.
All the authors read and approved the final manuscript.
Competing interests
N.G. D.H, S.U. and C.Sa. are members of NewVectys, which owns the
commercialization rights of the NILVs. S.P, J.M, C.Se. and C.Sa are listed as
inventors on patent applications related to NILVs. These conditions do not
alter the authors’ adherence to Genetic Vaccines and Therapy policies.
Materials and information associated with the authors’ publication will be
freely available to those as reasonably requested for the purpose of
academic, non-commercial research.
Received: 29 June 2010 Accepted: 4 January 2011
Published: 4 January 2011
References
1. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X, McCown T, Kafri T: A
large u3 deletion causes increased in vivo expression from a
nonintegrating lentiviral vector. Mol Ther 2008, 16:1968-1976.
2. Deglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, Pereira de
Almeida L, Zufferey R, Trono D, Aebischer P: Self-inactivating lentiviral
vectors with enhanced transgene expression as potential gene
transfer system in Parkinson’sd i s e a s e .Hum Gene Ther 2000,
11:179-190.
3. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM: Development of a
self-inactivating lentivirus vector. J Virol 1998, 72:8150-8157.
Table 1 Summary of statistically relevant effects of Ig and ChL MARs on transduction efficiency on various cells in
integrating (LV), double-copy (DC) and non-integrating (NILV) lentiviral vectors. (+) positive effect, (-) negative effect,
(0) no effect.
Vectors
LV Ig DC Ig NILV Ig LV ChL NILV ChL
Cells 293T + - +
Hela 0 - - 0
3T3 + 0 - -
Primary neural progenitors undifferentiated 0 0 0
Primary neural progenitors differentiated + - -
Raji 0
Jurkat +
Grandchamp et al. Genetic Vaccines and Therapy 2011, 9:1
http://www.gvt-journal.com/content/9/1/1
Page 7 of 84. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D: Self-
inactivating lentivirus vector for safe and efficient in vivo gene delivery.
J Virol 1998, 72:9873-9880.
5. Hawley RG, Covarrubias L, Hawley T, Mintz B: Handicapped retroviral
vectors efficiently transduce foreign genes into hematopoietic stem
cells. Proc Natl Acad Sci USA 1987, 84:2406-2410.
6. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L: Gene transfer by
lentiviral vectors is limited by nuclear translocation and rescued by HIV-
1 pol sequences. Nat Genet 2000, 25:217-222.
7. Sirven A, Ravet E, Charneau P, Zennou V, Coulombel L, Guetard D,
Pflumio F, Dubart-Kupperschmitt A: Enhanced transgene expression in
cord blood CD34(+)-derived hematopoietic cells, including developing T
cells and NOD/SCID mouse repopulating cells, following transduction
with modified trip lentiviral vectors. Mol Ther 2001, 3:438-448.
8. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P: HIV-1
genome nuclear import is mediated by a central DNA flap. Cell 2000,
101:173-185.
9. Zennou V, Serguera C, Sarkis C, Colin P, Perret E, Mallet J, Charneau P: The
HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the
brain. Nat Biotechnol 2001, 19:446-450.
10. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B,
Debyser Z: Characterization of lentiviral vector-mediated gene transfer in
adult mouse brain. Hum Gene Ther 2002, 13:841-853.
11. Zufferey R, Donello JE, Trono D, Hope TJ: Woodchuck hepatitis virus
posttranscriptional regulatory element enhances expression of
transgenes delivered by retroviral vectors. J Virol 1999, 73:2886-2892.
12. Brun S, Faucon-Biguet N, Mallet J: Optimization of transgene expression
at the posttranscriptional level in neural cells: implications for gene
therapy. Mol Ther 2003, 7:782-789.
13. Gaszner M, Felsenfeld G: Insulators: exploiting transcriptional and
epigenetic mechanisms. Nat Rev Genet 2006, 7:703-713.
14. Park F, Kay MA: Modified HIV-1 based lentiviral vectors have an effect on
viral transduction efficiency and gene expression in vitro and in vivo.
Mol Ther 2001, 4:164-173.
15. Ma Y, Ramezani A, Lewis R, Hawley RG, Thomson JA: High-level sustained
transgene expression in human embryonic stem cells using lentiviral
vectors. Stem Cells 2003, 21:111-117.
16. Ramezani A, Hawley TS, Hawley RG: Performance- and safety-enhanced
lentiviral vectors containing the human interferon-beta scaffold
attachment region and the chicken beta-globin insulator. Blood 2003,
101:4717-4724.
17. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P: Improved
human beta-globin expression from self-inactivating lentiviral vectors
carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol
Ther 2007, 15:1863-1871.
18. Robert-Richard E, Richard E, Malik P, Ged C, de Verneuil H, Moreau-
Gaudry F: Murine retroviral but not human cellular promoters induce in
vivo erythroid-specific deregulation that can be partially prevented by
insulators. Mol Ther 2007, 15:173-182.
19. Jakobsson J, Rosenqvist N, Thompson L, Barraud P, Lundberg C: Dynamics
of transgene expression in a neural stem cell line transduced with
lentiviral vectors incorporating the cHS4 insulator. Exp Cell Res 2004,
298:611-623.
20. Pikaart MJ, Recillas-Targa F, Felsenfeld G: Loss of transcriptional activity of
a transgene is accompanied by DNA methylation and histone
deacetylation and is prevented by insulators. Genes Dev 1998,
12:2852-2862.
21. Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA: Optimized
lentiviral vector design improves titer and transgene expression of
vectors containing the chicken beta-globin locus HS4 insulator element.
Mol Ther 2009, 17:667-674.
22. Nielsen TT, Jakobsson J, Rosenqvist N, Lundberg C: Incorporating double
copies of a chromatin insulator into lentiviral vectors results in less viral
integrants. BMC Biotechnol 2009, 9:13.
23. Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P,
Malik P: Mechanism of reduction in titers from lentivirus vectors carrying
large inserts in the 3’LTR. Mol Ther 2009, 17:1527-1536.
24. Kanda K, Hu HM, Zhang L, Grandchamps J, Boxer LM: NF-kappa B activity
is required for the deregulation of c-myc expression by the
immunoglobulin heavy chain enhancer. J Biol Chem 2000,
275:32338-32346.
25. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T: SATB1 reprogrammes
gene expression to promote breast tumour growth and metastasis.
Nature 2008, 452:187-193.
26. Arumugam PI, Higashimoto T, Urbinati F, Modlich U, Nestheide S, Xia P,
Fox C, Corsinotti A, Baum C, Malik P: Genotoxic potential of lineage-
specific lentivirus vectors carrying the beta-globin locus control region.
Mol Ther 2009, 17:1929-1937.
27. Desprat R, Bouhassira EE: Gene specificity of suppression of transgene-
mediated insertional transcriptional activation by the chicken HS4
insulator. PLoS One 2009, 4:e5956.
28. Li CL, Xiong D, Stamatoyannopoulos G, Emery DW: Genomic and
functional assays demonstrate reduced gammaretroviral vector
genotoxicity associated with use of the cHS4 chromatin insulator. Mol
Ther 2009, 17:716-724.
29. Hargrove PW, Kepes S, Hanawa H, Obenauer JC, Pei D, Cheng C, Gray JT,
Neale G, Persons DA: Globin lentiviral vector insertions can perturb the
expression of endogenous genes in beta-thalassemic hematopoietic
cells. Mol Ther 2008, 16:525-533.
30. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, Mallet J,
Serguera C: Lentiviral vectors with a defective integrase allow efficient
and sustained transgene expression in vitro and in vivo. Proc Natl Acad
Sci USA 2006, 103:17684-17689.
31. Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE,
Ward NJ, Philpott NJ, Cooper JD, Anderson PN, Waddington SN,
Thrasher AJ, Raivich G: Efficient gene delivery to the adult and fetal CNS
using pseudotyped non-integrating lentiviral vectors. Gene Ther 2009,
16:509-520.
32. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ,
Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, von
Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ: Effective gene
therapy with nonintegrating lentiviral vectors. Nat Med 2006, 12:348-353.
33. Philpott NJ, Thrasher AJ: Use of nonintegrating lentiviral vectors for gene
therapy. Hum Gene Ther 2007, 18:483-489.
34. Sarkis C, Philippe S, Mallet J, Serguera C: Non-integrating lentiviral vectors.
Curr Gene Ther 2008, 8:430-437.
35. Wanisch K, Yanez-Munoz RJ: Integration-deficient lentiviral vectors: a slow
coming of age. Mol Ther 2009, 17:1316-1332.
36. Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP,
Thrasher AJ, Collins MK, Philpott NJ: Stable gene transfer to muscle using
non-integrating lentiviral vectors. Mol Ther 2007, 15:1947-1954.
37. Cornu TI, Cathomen T: Targeted genome modifications using integrase-
deficient lentiviral vectors. Mol Ther 2007, 15:2107-2113.
38. Girod PA, Zahn-Zabal M, Mermod N: Use of the chicken lysozyme 5’
matrix attachment region to generate high producer CHO cell lines.
Biotechnol Bioeng 2005, 91:1-11.
39. Buchet D, Serguera C, Zennou V, Charneau P, Mallet J: Long-term
expression of beta-glucuronidase by genetically modified human neural
progenitor cells grafted into the mouse central nervous system. Mol Cell
Neurosci 2002, 19:389-401.
40. Kumar M, Keller B, Makalou N, Sutton RE: Systematic determination of the
packaging limit of lentiviral vectors. Hum Gene Ther 2001, 12:1893-1905.
41. Shin NH, Hartigan-O’Connor D, Pfeiffer JK, Telesnitsky A: Replication of
lengthened Moloney murine leukemia virus genomes is impaired at
multiple stages. J Virol 2000, 74:2694-2702.
42. Gotte M, Rausch JW, Marchand B, Sarafianos S, Le Grice SF: Reverse
transcriptase in motion: conformational dynamics of enzyme-substrate
interactions. Biochim Biophys Acta 2010, 1804:1202-1212.
43. Rinke CS, Boyer PL, Sullivan MD, Hughes SH, Linial ML: Mutation of the
catalytic domain of the foamy virus reverse transcriptase leads to loss of
processivity and infectivity. J Virol 2002, 76:7560-7570.
doi:10.1186/1479-0556-9-1
Cite this article as: Grandchamp et al.: Influence of insulators on
transgene expression from integrating and non-integrating lentiviral
vectors. Genetic Vaccines and Therapy 2011 9:1.
Grandchamp et al. Genetic Vaccines and Therapy 2011, 9:1
http://www.gvt-journal.com/content/9/1/1
Page 8 of 8